J&J/Millenium Studying Velcade/Rituxan Combo For Treatment Of NHL
This article was originally published in The Pink Sheet Daily
Executive Summary
Millennium and development partner Johnson & Johnson have initiated a Phase III trial evaluating Velcade (bortezomib) in combination with Genentech/Biogen Idec's Rituxan (rituximab) in the treatment of refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma, the companies announced April 18
You may also be interested in...
Velcade sNDA Submitted For Mantle Cell Lymphoma Indication
Millennium/J&J injection demonstrated a 33% overall response rate among treated patients with the aggressive cancer.
Velcade sNDA Submitted For Mantle Cell Lymphoma Indication
Millennium/J&J injection demonstrated a 33% overall response rate among treated patients with the aggressive cancer.
Rituxan Submitted For Third Indication In 2006
Genentech submits Rituxan sBLA to treat indolent frontline non-Hodgkin’s lymphoma.